With a number of data events expected in the coming months, we remain focused on advancing our programs in chronic urticaria and continue to ...
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit ...
Jasper plans to report final conclusions from the investigation in the fourth quarter of 2025, supported by a key opinion leader panel that will review findings and provide clinical and chemistry, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback